CytoMed Therapeutics Limited Research and Development Expense
CytoMed Therapeutics Limited (GDTC) reported Research and Development Expense of SGD 2.22 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2026-03-31
SGD
| Period end | Research And Development Expense 12 month |
|---|---|
| 2025-12-31 | 2.22M SGD 20-F · filed 2026-03-31 |
| 2024-12-31 | 1.91M SGD 20-F · filed 2026-03-31 |
| 2023-12-31 | 1.59M SGD 20-F · filed 2026-03-31 |
| 2022-12-31 | 1.52M SGD 20-F · filed 2025-04-28 |
| 2021-12-31 | 1.09M SGD 20-F · filed 2024-04-22 |
| 2020-12-31 | 1.04M SGD 20-F · filed 2023-05-01 |
USD
| Period end | Research And Development Expense 12 month |
|---|---|
| 2025-12-31 | $1.72M 20-F · filed 2026-03-31 |
| 2024-12-31 | $1.40M 20-F · filed 2025-04-28 |
| 2023-12-31 | $1.20M 20-F · filed 2024-04-22 |
| 2022-12-31 | $1.14M 20-F · filed 2023-05-01 |